Observational studyChest2019
Low and High Blood Eosinophil Counts as Biomarkers in Hospitalized Acute Exacerbations of COPD.
Observational study in Chest, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- High blood eosinophils predict the risk of COPD exacerbation: A systematic review and meta-analysis.PloS one · 2024Pooled it
- Prognostic risk factors for moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease: a systematic literature review.Respiratory research · 2022Pooled it
- Peripheral Blood Inflammatory Markers and Immune Cell Profiles in Smokers With and Without COPD.Pulmonary therapy · 2026Article
- CT image-based machine learning models for predicting blood eosinophil levels in acute exacerbation of chronic obstructive pulmonary disease.BMC pulmonary medicine · 2026Article
- Severe COPD Exacerbators Requiring Multiple ICU Admissions Over Time: Insights of a French Cohort.International journal of chronic obstructive pulmonary disease · 2026Article
- The Prognostic Role of Different Blood Cell Count-to-Lymphocyte Ratios in Patients with Lung Cancer at Diagnosis.Cancers · 2025Article
- Type 2 inflammation in chronic obstructive pulmonary disease: A promising treatable trait and practice recommendations.Chinese medical journal pulmonary and critical care medicine · 2025Article
- Development and validation of a machine learning-based model to predict the risk of hospitalization death in hospitalized patients with AECOPD.Scientific reports · 2025Article
- Article
- Article
- Association between eosinophil count and prognosis in chronic obstructive pulmonary disease patients.Frontiers in medicine · 2025Article
- Clinical Characteristics and Outcomes of Eosinophilic Exacerbations of COPD.International journal of chronic obstructive pulmonary disease · 2025Article
- Clinical Characteristics of Overweight Patients With Acute Exacerbation Chronic Obstructive Pulmonary Disease (AECOPD).The clinical respiratory journal · 2024Article
- Clinical Characteristics and Outcomes of Hospitalized AECOPDs Secondary to SARS-CoV-2 versus Other Respiratory Viruses.International journal of chronic obstructive pulmonary disease · 2024Article
- Comprehensive Nomograms Using Routine Biomarkers Beyond Eosinophil Levels: Enhancing Predictability of Corticosteroid Treatment Outcomes in AECOPD.Journal of inflammation research · 2024Article
- Blood Eosinophil Count and Its Determinants in a Chinese Population-Based Cohort.Respiration; international review of thoracic diseases · 2024Article
- A Low Eosinophil to Platelet Ratio as a Worse Prognostic Index for Emergency Department Attendance in Acute Exacerbation of COPD.International journal of chronic obstructive pulmonary disease · 2024Article
- Article
- Eosinopenia as a Prognostic Biomarker for Noninvasive Ventilation Use in COPD Exacerbations.Journal of personalized medicine · 2023Article
- Clinical Implications of Low Absolute Blood Eosinophil Count in the SPIROMICS COPD Cohort.Chest · 2023Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCharacterizing acute exacerbations of COPD (AECOPD) and individualizing therapy is challenging. Key exacerbation therapies include antibiotics and systemic corticosteroids. Blood eosinophils, when either low or high, may offer a simple, inexpensive distinction to predict beneficial responses to these therapies.
methodsWe conducted derivation (n = 242) and validation (n = 99) cohort studies of patients hospitalized for AECOPD. Patients who received oral corticosteroids before ED presentation were excluded. The derivation cohort was identified by individual case file review. The validation cohort was prospectively recruited during hospital admission. Exacerbations were grouped according to blood eosinophil count as low (<50/μL), normal (50-150/μL), or high (>150/μL). Exacerbations were classified as being associated with infection if either virus testing was positive or C-reactive protein was ≥20 mg/L. Associations of eosinophil groups with infection, hospital length of stay, and 12-month survival were compared using appropriate statistical methods.
resultsThere were no significant differences in baseline characteristics between patients with low, normal, or high blood eosinophils in either cohort. Eosinophil counts <50/μL were more strongly associated with infection (91% vs 51.9%, P = .001), distinguished patients with longer median hospital stays (7 vs 4 days, P < .001), and were associated with lower 12-month survival (82.4% vs 90.7%, P = .028; pooled data of both cohorts) than eosinophil counts >150/μL.
conclusionsLow and high blood eosinophil counts in hospitalized patients with AECOPD provide a practical clinical distinction that can potentially be used to inform management strategies. Prospective studies are needed to evaluate if this strategy can guide discriminate use of antibiotics and/or corticosteroids.
Indexed as
Identifiers
30978330What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.